Del Labs S&E
This article was originally published in The Rose Sheet
Executive SummaryNet sales for the year increased 12.8% to $332.7 mil. and net earnings more than doubled to $9.8 mil., Uniondale, N.Y. company says Feb. 21. In the fourth quarter, sales were up 16.4% to $85.7 mil., and earnings increased 149.6% to $2.8 mil. Growth is attributed to Del's flagship brand Sally Hansen, as well as N.Y.C. New York Color. For spring, Del will launch Sally Hansen's Age Correct Growth Treatment, Diamond Strength Instant Nail Hardener and a four-SKU Advanced Hand Care line. All products will retail for $5.95...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.